Navigation Links
InspireMD To Participate In Benchmark Investor Conference On May 30th
Date:5/24/2013

ative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multi-national companies, (v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Transition Report on Form 10-K/T and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

For additional information:
'/>"/>

SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. InspireMD Hires Vice President of Corporate Development
2. Michael Berman Joins InspireMD Board
3. InspireMD Postpones $40 Million Registered
4. InspireMD Reports 2012 Fiscal Year Results
5. InspireMD to Present at JMP Securities Healthcare Conference on July 12th in New York
6. InspireMD to Present at JMP Securities Healthcare Conferenceon July 12th in New York
7. InspireMD Appoints Dr. James Barry to Its Board of Directors
8. InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors
9. ViroPharma To Participate In Two May Healthcare Investor Conferences
10. P&P Optica Invited to Cambridge Innovation Centre for the Canadian Technology Accelerator Program, One of Eight Canadian Life Science Companies Chosen to Participate
11. AVANIR Pharmaceuticals To participate in two conferences in March
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
(Date:12/22/2014)... 2014  Alternative Energy & Environmental Solutions, Inc., ... a letter of intent to acquire BioTechPharma Corporation, ... a nanotechnology-based development platform used to create drug ... on-site collection and testing to identify infectious disease, ... an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... Illinois (PRWEB) December 22, 2014 ITRA ... tenants and occupiers of commercial real estate, has further ... new offices in Perth and Brisbane, Western Australia, reports ... of directors. , ITRA Global / ACORPP (Australian ... totally independent consultancy company providing property services to a ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3ALNE Announces Intention To Acquire BioTechPharma 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... Europe,s premier biotech conference continues to grow and ... business network which provides comprehensive support for bioscience businesses ... today announced the results of the sixth annual BioTrinity ... 26 at Newbury Racecourse, UK, BioTrinity is now firmly ...
... April 25, 2012  Quest Diagnostics (NYSE: DGX ... and services, today announced a new genetic testing service ... neurology diagnostics, for amyotrophic lateral sclerosis (ALS), also known ... the first clinically available testing service for detecting hexanucleotide repeat ...
... --  The Society of Chemical Manufacturers and ... SCD-iBIO , a new affiliate group that aims to ... application of biology for the production and processing of ... group is referred to by its acronym, which stands ...
Cached Biology Technology:Another Record Year for BioTrinity 2Another Record Year for BioTrinity 3Quest Diagnostics Announces C9orf72 Genetic Test for ALS (Lou Gehrig's Disease) 2Quest Diagnostics Announces C9orf72 Genetic Test for ALS (Lou Gehrig's Disease) 3SOCMA Announces Launch of SCD-iBIO Group 2
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
(Date:12/10/2014)...     Jifflenow ...   Jifflenow, a leading provider ... business-to-business (B2B) events, today announced a partnership with ... communication (NFC), Bluetooth low energy (BLE), and cloud-based ... Jifflenow will integrate its meeting scheduling ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... on islands are highly vulnerable to introduced rats, which find ... impacts of rats on islands extend far beyond seabird nesting ... University of California, Santa Cruz. The study, which ... the Proceedings of the National Academy of Sciences, has already ...
... of cell biology is to explain cellular activities ... needs to quantify molecular concentrations and aggregation states ... various complex processes. For a complex cellular ... localized, transient component processes, the need is for ...
... State University researchers helped write the first draft of ... Feb. 28, at the 50th Annual Maize Genetics Conference ... of Agronomy and director of the Center for Plant ... Srinivas Aluru, a Stanley Chair in Interdisciplinary Engineering and ...
Cached Biology News:Rats on islands disrupt ecosystems from land to sea, researchers find 2Rats on islands disrupt ecosystems from land to sea, researchers find 3Iowa State researchers help piece together the corn genome's first draft 2Iowa State researchers help piece together the corn genome's first draft 3Iowa State researchers help piece together the corn genome's first draft 4
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Rabbit polyclonal to TetR ( Abpromise for all tested applications). Antigen: Synthetic peptide: AQKLGVEQPTLYWHVKNKR, corresponding to amino acids 31 - 49 of TetR...
Polyclonal Antibody to Coronin / CORO1C This antibody was developed against synthetic peptides corresponding to amino acids 407-420 of human CORO1C....
Peptide-affinity Purified Polyclonal Antibody to Histamine H2 Receptor...
Biology Products: